Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Downgrades Nevro to Neutral, Lowers Price Target to $150

Baird analyst Mike Polark downgrades Nevro (NYSE:NVRO) from Outperform to Neutral and lowers the price target from $188 to $150.

byBenzinga Newsdesk

July 6, 2021

1 minute read

Baird analyst Mike Polark downgrades Nevro (NYSE:NVRO) from Outperform to Neutral and lowers the price target from $188 to $150.

Analyst Ratings

14 Analysts Have This to Say About Tesla

By Benzinga Insights

Today, 6:35 AM

Within the last quarter, Tesla (NASDAQ:TSLA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

TSLA

What’s Going On With Cannabis Pricing In Illinois? Analyst Examines Retailers’ Menus

By Nicolas Jose Rodriguez

Today, 6:35 AM

Illinois is one of the most prominent cannabis markets in the U.S. In 2022, recreational marijuana sales crossed the $1 billion mark.

AAWH

Credit Suisse Downgrades First American Financial to Neutral, Lowers Price Target to $74

By Benzinga Newsdesk

Today, 6:35 AM

Credit Suisse analyst Andrew Kligerman downgrades First American Financial (NYSE:FAF) from Outperform to Neutral and lowers the price target from $97 to $74.

FAF

Graphite Bio’s Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

By Nikhil Dayal

Today, 6:35 AM

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.

GRPH

Baird Downgrades Nevro to Neutral, Lowers Price Target to $150

Related Posts

14 Analysts Have This to Say About Tesla

What’s Going On With Cannabis Pricing In Illinois? Analyst Examines Retailers’ Menus

Credit Suisse Downgrades First American Financial to Neutral, Lowers Price Target to $74

Graphite Bio’s Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish